Safety

Science-backed. Clinically proven. Trusted by professionals.

For Tience®, safety is not just a requirement, it’s the foundation of our innovation. Every stage of development, production, and clinical use is designed to meet the highest medical and regulatory standards. Your skin deserves treatments that are not only effective but proven safe. Tience® is developed in Finland under strict EU regulations for products of human-origin, with safety as the foundation of every step.

Safety testing confirms that Tience® does not cause harmful effects in the body when applied locally.1 Advanced laboratory analyses show that Tience® contains no significant toxic or immune-triggering components, only safe, skin-compatible ingredients.2 No systemic toxicity has been observed, even after multiple treatments.3 This means it can be used safely for repeated treatments over time.

What Is Tience® Made From?

Tience® is manufactured from carefully selected human adipose tissue (subcutaneous fat). It is a rich source of skin-regenerating bioactive molecules such as bioactive peptides, lipids, and antioxidants.

Because it comes from natural human tissue, it contains nothing foreign to the skin, only safe, functional components your skin already knows how to use. Tience® is a cell-free, sterile product that contains no antigens capable of triggering severe immune reactions, while preserving strong regenerative effects.

1. Stringent Quality Controls

Before any Tience® product reaches a clinic, it passes multi-stage testing:

  • Donor safety screening – ensuring only safe, high-quality subcutaneous fat is used.

  • Sterility & endotoxin testing – ensuring the product is pure and clean.

  • Protein content & bioactivity testing – confirming effectiveness.

2. Proven Safe in Clinical Use

  • In use since 2022 – over 1,500 treatments administered.4
  • 0 adverse reactions*
  • Multiple clinical studies1,5,6,7, including randomized controlled trials, show:
  1. No allergic reactions
  2. No skin irritation
  3. No systemic or long-term toxic effects

* Tience-related adverse events. Injection-related adverse events are common: pinpoint bleeding, acute bruising, acute swelling, pain at the injection site, itching, tingling, needle marks

3. Regulatory Compliance

Tience® is manufactured and monitored under:

  • EU Tissue Directives (2004/23/EC, 2006/17/EC, and 2006/86/EC). 8,9,10

  • Finnish legislation (Law 101/2001, Decree 594/2001, and Decree 1302/2007).11

  • Fimea (Finnish Medicines Agency) approval and auditing.12

  • Meets local regulatory requirements in: Finland, Sweden, France, Ireland, Norway, Denmark, Estonia, Austria, Luxemburg.

  • Manufactured according to Linio Biotech’s certified quality management system (TE4008).

4. Continuous monitoring of safety

We collect real-world safety feedback from clinics to ensure continued safety and performance. Any reported feedback is reviewed and addressed immediately. With excellent safety record, strict regulatory compliance, and ongoing clinical monitoring, Tience® sets a new standard for safe, science-based regenerative aesthetics.


Tience® is a low-risk, scientifically tested regenerative treatment – proven safe when used by trained professionals, following the instructions for use.

References

1. Safety study evaluating the safety and tolerability of the Linio tissue product in healthy volunteers. Clinical Investigation Report. 17.3.2023. Clinius Oy

2. Data on file. Characterization of cell-free adipose tissue preparate. Hautanen V., ongoing PhD study, University of Tampere.

3. Data on file. Leppänen Minna, Kipar Anja, Mäkelä Tiina, Sarkanen Jertta-Riina, Ylikomi Timo. Study report, 2017. Pre-clinical safety evaluation of bioactive adipose tissue extract – long term repeated dose systemic toxicity study.

4. Data on file. Clinical follow-up of Tience use, 2022-

5. Adipose tissue as a source of growth factors to promote wound healing: a human study of skin graft donor sites. López JF, Mikkola A, Sarkanen JR, Kaartinen IS, Kuokkanen HO, Ylikomi T. Wound Care. 2022 Apr 2;31(4):282-92.

6. The effect of allogeneic human fat-derived extract on skin graft donor site wound healing. Clinical Investigation Plan. 2022. (ongoing)

7. The suitability of Tience® for the treatment of acne scars. Clinical Investigation Plan. 2025. (ongoing)

8. Directive 2004/23/EC Of The European Parliament And Of The Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.

9. Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells.

10. Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells.

11. 101/2001 Laki ihmisen elimien, kudoksien ja solujen lääketieteellisestä käytöstä. Sosiaali- ja terveysministeriö 1.9.2001

12. 3/2014 Lääkealan turvallisuus- ja kehittämiskeskuksen määräys. Kudoslaitostoiminta.